aNeuSTART

Company Overview

Snapshot

Founded in March 2018 by Yael Kuperman and Maya Lebow, aNeuSTART operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a noninvasive, at-home diagnostic kit for children with Autism Spectrum Disorder.

Business overview

aNeuSTART develops a nutrient-based, precision-targeted, personalized action plan for children with Autism Spectrum Disorder. The company's core technology is a noninvasive, at-home diagnostic kit that identifies biological pathways impacting nutritional flow to the brain, combined with an algorithm that processes diagnostic results, health history, symptoms, and diet. This enables personalized recommendations for supplements and foods. aNeuSTART operates in the Health Tech & Life Sciences sector, specifically within Digital Health and Medical Technologies, serving global markets with a focus on patients and healthcare providers.

Company Intelligence Q&A

What is aNeuSTART's primary focus?

aNeuSTART focuses on developing a nutrient-based, precision-targeted, personalized action plan for children with autism spectrum disorder to improve their overall functioning.

What technology does aNeuSTART utilize?

aNeuSTART is developing a noninvasive, at-home diagnostic kit that detects biological pathways affecting nutritional flow to the brain, paired with an algorithm that processes this data alongside patient health history, symptoms, and diet.

Who are the founders of aNeuSTART?

aNeuSTART was co-founded by Yael Kuperman and Maya Lebow in March 2018.

What kind of recommendations does aNeuSTART provide?

Based on the diagnostic kit results and patient data, aNeuSTART provides personalized recommendations for supplements and foods tailored to the child's age, symptoms, and preferences to restore proper biochemical pathway functioning.

In which sector does aNeuSTART operate?

aNeuSTART operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Therapeutics.